The present invention provides an anti-inflammatory, analgesic and fast-healing external traditional Chinese medicine preparation and its preparation method. The traditional Chinese medicine preparation includes following components in parts by weight: 30-80 parts of corydalis tuber, 20-90 parts of maifanitum, 20-50 parts of radix aconiti kusnezoffii praeparata, 10-45 parts of common clubmoss herb, 10-40 parts of clematis root, 10-40 parts of safflower, 5-40 parts of bryozoatum and 5-35 parts of oyster shell. The traditional Chinese medicine preparation has advantages of unique prescription, reasonable ratio, advanced preparation process, high active ingredient content, fast absorption, no irritation of ethanol preparation to the skin, convenient use, direct effect on the lesion location, fast and significant curative effect and no adverse effect on organs of the human body.

The present invention provides an anti-inflammatory, analgesic and fast-healing external traditional Chinese medicine preparation and its preparation method. The traditional Chinese medicine preparation includes following components in parts by weight: 30-80 parts of corydalis tuber, 20-90 parts of maifanitum, 20-50 parts of radix aconiti kusnezoffii praeparata, 10-45 parts of common clubmoss herb, 10-40 parts of clematis root, 10-40 parts of safflower, 5-40 parts of bryozoatum and 5-35 parts of oyster shell. The traditional Chinese medicine preparation has advantages of unique prescription, reasonable ratio, advanced preparation process, high active ingredient content, fast absorption, no irritation of ethanol preparation to the skin, convenient use, direct effect on the lesion location, fast and significant curative effect and no adverse effect on organs of the human body.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-, lactoferrin, IFN-, IL-1, serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-, lactoferrin, IFN-, IL-1, serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.